Eltrombopag in patients with chronic liver disease

Bibliography

• Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol 2008;15:473-80
   PubMed Web of Science ®Google Scholar
• Louie KS, Micallef JM, Pimenta JM, Forssen UM. Prevalence of thrombocytopenia among chronic hepatitis C patients: a systematic review. J Viral Hepat 2011;18:1-7
   PubMed Web of Science ®Google Scholar
• Giannini EG, Savarino V. Epidemiology of thrombocytopenia in patients with chronic hepatitis C: more than meets the eye. J Viral Hepat 2011;18:8-10
   PubMedGoogle Scholar
• Qamar MM, Grace ND, Groszmann RJ, Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol 2009;7:689-95
   PubMed Web of Science ®Google Scholar
• Giannini EG, Marenco S, Fazio V, Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. Liver Int 2012;32:1113-19
   PubMed Web of Science ®Google Scholar
• Lin KH, Hsu PI, Lin CK, Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis C and pretreatment low platelet counts. BMC Gastroenterol 2012;12:7
   PubMed Web of Science ®Google Scholar
• Giannini EG, Greco A, Marenco S, Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol 2010;8:899-902
   PubMed Web of Science ®Google Scholar
• Peck-Radosavljevic M, Zacherl J, Meng YG, Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997;27:127-31
   PubMed Web of Science ®Google Scholar
• Giannini E, Borro P, Botta F, Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol 2002;37:572-7
   PubMed Web of Science ®Google Scholar
• Giannini E, Botta F, Borro P, Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. Am J Gastroenterol 2003;98:2516-20
   PubMed Web of Science ®Google Scholar
• Giannini EG, Savarino V. Further insights into the causes of thrombocytopenia in chronic hepatitis C. J Gastrointestin Liver Dis 2010;19:357-8
   PubMed Web of Science ®Google Scholar
• Wolber EM, Jelkmann W. Thrombopoietin: the novel hepatic hormone. News Physiol Sci 2002;17:6-10
   PubMedGoogle Scholar
• Nichol JL. Endogenous TPO (eTPO) level in health and disease: possible clues for therapeutic intervention. Stem Cells 1998;16(Suppl 2):165-75
   PubMedGoogle Scholar
• Martin TG, Somberg KA, Meng YG, Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997;127:285-8
   PubMed Web of Science ®Google Scholar
• Peck-Radosavljevic M, Wichlas M, Zacherl J, Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000;95:795-801
   PubMed Web of Science ®Google Scholar
• Stroncek DF, Rebulla P. Platelet transfusions. Lancet 2007;370:427-38
   PubMed Web of Science ®Google Scholar
• de Boer MT, Christensen MC, Asmussen M, The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg 2008;106:32-44
   PubMed Web of Science ®Google Scholar
• Pereboom IT, de Boer MT, Haagsma EB, Platelet transfusion during liver transplantation is associated with increased postoperative mortality due to acute lung injury. Anesth Analg 2009;108:1083-91
   PubMed Web of Science ®Google Scholar
• Kuter DJ. New thrombopoietic growth factors. Blood 2007;109:4607-16
   PubMed Web of Science ®Google Scholar
• Romiplostim. Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000942/WC500039537.pdf [Accessed 5 November 2012]
   Google Scholar
• Eltrombopag. Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/001110/WC500089964.pdf [Accessed 5 November 2012]
   Google Scholar
• Afdhal N, Giannini EG, Tayyab G, Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012;367:716-24
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Dusheiko G, Giannini EG, Final results of ENABLE 1, a phase 3, multicenter study of eltrombopag as an adjunct for antiviral treatment of hepatitis C virus-related chronic liver disease associated with thrombocytopenia. Hepatology 2011;54(Suppl 1):1427-8
   Google Scholar
• Dusheiko G, Afdhal N, Giannini EG, Results of ENABLE 2, a phase 3, multicenter study of eltrombopag and peginterferon alfa-2b treatment in patients with hepatitis C and thrombocytopenia. J Hepatol 2012;56(Suppl 2):S27
   Google Scholar
• Luengo JI, Duffy KJ, Shaw AN, Discovery of SB-497115, a small-molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia. Blood 2004;104:795A
   PubMedGoogle Scholar
• Erickson-Miller CL, DeLorme E, Tian SS, Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005;33:85-93
   PubMed Web of Science ®Google Scholar
• Erickson Miller CL, Delorme E, Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009;27:424-30
   PubMedGoogle Scholar
• Erhardt JA, Erickson-Miller CL, Aivado M, Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009;37:1030-7
   PubMed Web of Science ®Google Scholar
• Jenkins JM, Williams D, Deng Y, Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109:4739-41
   PubMed Web of Science ®Google Scholar
• Deng Y, Madatian A, Wire MB, Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects. Drug Metab Disp 2011;39:1734-46
   PubMedGoogle Scholar
• Williams DD, Peng B, Bailey CK, Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther 2009;31:764-76
   PubMed Web of Science ®Google Scholar
• Deng Y, Rogers M, Sychterz C, Investigations of hydrazine cleavage of eltrombopag in humans. Drug Metab Dispos 2011;39:1747-54
   PubMed Web of Science ®Google Scholar
• Jenkins J, Williams D, Deng Y, Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. Eur J Clin Pharmacol 2010;66:67-76
   PubMed Web of Science ®Google Scholar
• Bauman JW, Vincent CT, Peng B, Effect of hepatic or renal impairment on eltrombopag pharmacokinetics. J Clin Pharmacol 2011;51:739-50
   PubMed Web of Science ®Google Scholar
• Pugh RNH, Murray-Lyon IM, Dawson JL, Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9
   PubMed Web of Science ®Google Scholar
• Matthys G, Park JW, McGuire S, Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects. Br J Clin Pharmacol 2010;70:24-33
   PubMedGoogle Scholar
• McHutchison JG, Dusheiko G, Shiffman ML, Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-36
   PubMed Web of Science ®Google Scholar
• Gibiansky E, Zhang J, Williams D, Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol 2011;51:842-56
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Komori A, Seike M, Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study. J Gastroenterol 2012;47:1342-51
   PubMed Web of Science ®Google Scholar
• Kamath PS, Wiesner RH, Malinchoc M, A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70
   PubMed Web of Science ®Google Scholar
• Botta F, Giannini E, Romagnoli P, MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 2003;52:134-9
   PubMed Web of Science ®Google Scholar
• Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn 2005;5:15-21
   PubMed Web of Science ®Google Scholar
• Pegasys (peginterferon alfa-2a). Complete prescribing information. Genentech, Inc, South San Francisco, CA; 2011
   Google Scholar
• PegIntron (peginterferon alfa-2b). Complete prescribing information. Schering Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ; 2011
   Google Scholar
• Giannini EG, Afdhal NH, Campbell FM, Exploratory analyses of predictors of thrombotic events in the ELEVATE study. Hepatology 2010;52(Suppl 1):1071A
   Google Scholar
• Violi F, Pignatelli P. Comment on: eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012;367:2055-6
   PubMedGoogle Scholar
• Lisman T, Bongers TN, Adelmeijer J, Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006;44:53-61
   PubMed Web of Science ®Google Scholar
• Tripodi A, Primignani M, Chantarangkul V, An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009;137:2105-11
   PubMed Web of Science ®Google Scholar
• Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011;365:147-56
   PubMed Web of Science ®Google Scholar
• Dusheiko G, Afdhal NH, Giannini E, Final results of open-label treatment with eltrombopag during ENABLE 1: a study of eltrombopag as an adjunct for antiviral treatment of hepatitis C virus associated with thrombocytopenia. Blood 2011;118:972
   Google Scholar
• Giannini E, Dusheiko G, Afdhal N, Eltrombopag raises platelet counts prior to antiviral therapy in patients with chronic hepatitis C virus infection associated with thrombocytopenia. Haematologica 2012;97(Suppl 1):O0609
   Google Scholar
• Saleh MN, Bussel JB, Cheng G, Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia (ITP): results of the long-term, open-label EXTEND study. Blood 2013;121:537-45
   PubMed Web of Science ®Google Scholar